RADX
Radiopharm Theranostics Limited
Price Chart
Latest Quote
$1.00
-0.01 (-1.39%)
Current Price
| Previous Close | $1.01 |
| Open | $0.96 |
| Day High | $1.06 |
| Day Low | $0.96 |
| Volume | 17,271 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 14.59M |
| Cash Equivalents | $2.91M |
| Revenue | $9.04M |
| Net Income | $-40.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.13M |
| EPS (TTM) | $-3.64 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.90M |
| Sales | $9.04M |
| Income | $-40.02M |
| Book/sh | $1.48 |
| Cash/sh | $0.28 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 1.14 |
| Current Ratio | 1.16 |
Returns & Margins
| ROA | -45.15% |
| ROE | -174.71% |
| Gross Margin | -266.89% |
| Operating Margin | -400.35% |
Ownership
| Institutional Ownership | 0.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.39 |
| P/S | 1.02 |
| P/B | 0.61 |
Analyst Data
| Recommendation | none |
| Target Price | $17.15 |
Technical Indicators
| SMA20 | $1.13 |
| SMA50 | $1.67 |
| SMA200 | $3.74 |
| RSI | 30.59 |
| ATR | 0.1606 |
| Shares Float | 11.96M |
| Short Float | 0.26% |
| Short Ratio | 0.67 |
| Volatility | 0.86 |
| Rel Volume | 0.51 |
Performance History
| Week | -9.09% |
| Month | -40.79% |
| Quarter | -71.43% |
| 6 Months | -79.45% |
| YTD | -82.56% |
| Year | -83.11% |
| 10 Years | -94.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $0.90 | 24,827 |
| 2026-10-26 | $1.00 | 17,300 |
| 2026-10-23 | $1.01 | 32,500 |
| 2026-10-22 | $0.95 | 15,800 |
| 2026-10-21 | $0.98 | 14,400 |
| 2026-10-20 | $0.99 | 31,400 |
| 2026-10-19 | $0.96 | 12,900 |
| 2026-10-16 | $1.03 | 106,400 |
| 2026-10-15 | $1.08 | 65,900 |
| 2026-10-14 | $1.12 | 39,200 |
| 2026-10-13 | $1.20 | 143,100 |
| 2026-10-12 | $1.11 | 9,600 |
| 2026-10-09 | $1.13 | 65,800 |
| 2026-10-08 | $1.11 | 26,700 |
| 2026-10-07 | $1.15 | 42,400 |
| 2026-10-06 | $1.18 | 77,500 |
| 2026-10-05 | $1.27 | 82,300 |
| 2026-10-02 | $1.42 | 62,300 |
| 2026-10-01 | $1.48 | 48,000 |
| 2026-09-30 | $1.62 | 63,400 |
| 2026-09-29 | $1.52 | 42,900 |
| 2026-09-28 | $1.52 | 44,000 |
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are AvÃ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
đ° Latest News
No news articles available at the moment. Check back later for updates on RADX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,509,528 | $0 | $0 | - |
| Cost Of Revenue | $2,509,528 | $0 | $0 | - |
| Total Revenue | $2,536,952 | $208,929 | $204,133 | $6,166 |
| Operating Revenue | $2,536,952 | $208,929 | $204,133 | $6,166 |
| Expenses | ||||
| Interest Expense | $45,594 | $448,881 | $60,111 | $6,528,236 |
| Total Expenses | $26,724,031 | $26,164,721 | $22,331,350 | $13,912,291 |
| Other Income Expense | $-2,745,105 | $-7,298,691 | $-2,053,856 | $-718,120 |
| Net Non Operating Interest Income Expense | $232,586 | $-157,579 | $41,156 | $-6,528,236 |
| Total Other Finance Cost | $341,982 | $-256,053 | - | - |
| Interest Expense Non Operating | $45,594 | $448,881 | $60,111 | $6,528,236 |
| Operating Expense | $24,214,503 | $26,164,721 | $22,331,350 | $13,912,291 |
| Other Operating Expenses | $-6,541,366 | $-902,512 | $-4,131,744 | $1,121,910 |
| General And Administrative Expense | $11,538,912 | $10,942,529 | $10,656,600 | $7,828,619 |
| Other Non Operating Income Expenses | - | $-5,284,025 | $4,131,744 | $-718,120 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Net Interest Income | $232,586 | $-157,579 | $41,156 | $-6,528,236 |
| Interest Income | $620,162 | $35,249 | $101,267 | - |
| Normalized Income | $-24,850,146 | $-28,370,262 | $-22,728,754 | $-20,680,795 |
| Net Income From Continuing And Discontinued Operation | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Total Operating Income As Reported | $-26,654,004 | $-32,963,180 | $-24,079,806 | - |
| Net Income Common Stockholders | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Net Income | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Net Income Including Noncontrolling Interests | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Net Income Continuous Operations | $-26,771,720 | $-33,479,346 | $-24,166,453 | $-21,183,479 |
| Pretax Income | $-26,699,598 | $-33,412,062 | $-24,139,917 | $-21,152,480 |
| Special Income Charges | $-2,841,558 | $-7,364,997 | $-1,874,236 | - |
| Interest Income Non Operating | $620,162 | $35,249 | $101,267 | - |
| Operating Income | $-24,187,079 | $-25,955,792 | $-22,127,217 | $-13,906,125 |
| Depreciation Amortization Depletion Income Statement | $5,119 | $5,260 | $4,575 | $2,081,751 |
| Depreciation And Amortization In Income Statement | $5,119 | $5,260 | $4,575 | $2,081,751 |
| Depreciation Income Statement | $5,119 | $5,260 | $4,575 | $818 |
| Gross Profit | $27,424 | $208,929 | $204,133 | $6,166 |
| Amortization Of Intangibles Income Statement | - | $2,177,595 | $2,297,151 | $2,080,934 |
| Per Share | ||||
| Diluted EPS | $-3.69 | $-25.99 | $-22.39 | $-32.01 |
| Basic EPS | $-3.69 | $-25.99 | $-22.39 | $-32.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $-823,531 | $-2,189,607 | $-616,157 | $-215,436 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-23,903,781 | $-25,659,229 | $-22,021,375 | $-11,824,374 |
| Total Unusual Items | $-2,745,105 | $-7,298,691 | $-2,053,856 | $-718,120 |
| Total Unusual Items Excluding Goodwill | $-2,745,105 | $-7,298,691 | $-2,053,856 | $-718,120 |
| Reconciled Depreciation | $5,119 | $5,260 | $4,575 | $2,081,751 |
| EBITDA (Bullshit earnings) | $-26,648,885 | $-32,957,920 | $-24,075,230 | $-12,542,493 |
| EBIT | $-26,654,004 | $-32,963,180 | $-24,079,806 | $-14,624,244 |
| Diluted Average Shares | $4,853,612 | $899,455 | $753,657 | $462,026 |
| Basic Average Shares | $4,853,612 | $899,455 | $753,657 | $462,026 |
| Diluted NI Availto Com Stockholders | $-26,771,720 | $-33,479,346 | $-24,166,453 | - |
| Tax Provision | $72,121 | $67,284 | $26,536 | $30,999 |
| Gain On Sale Of Ppe | $0 | $-1,178,460 | $0 | - |
| Restructuring And Mergern Acquisition | $2,841,558 | $6,186,537 | $1,874,236 | - |
| Gain On Sale Of Security | $96,454 | $66,306 | $-179,619 | $-718,120 |
| Research And Development | $19,211,838 | $16,119,443 | $15,801,919 | $2,880,011 |
| Selling General And Administration | $11,538,912 | $10,942,529 | $10,656,600 | $7,828,619 |
| Other Gand A | $3,075,528 | $2,250,890 | $3,763,279 | $1,375,239 |
| Insurance And Claims | $73,846 | $250,809 | $478,574 | - |
| Salaries And Wages | $8,389,538 | $8,440,830 | $6,414,747 | $6,453,380 |
| Impairment Of Capital Assets | - | $1,032,602 | $2,164,502 | - |
| Amortization | - | $2,177,595 | $2,297,151 | $2,080,934 |
Fetched: 2026-10-19
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,244,531 | $-14,638,127 | $-9,884,615 | $4,808,973 |
| Total Assets | $60,383,938 | $50,297,685 | $52,331,844 | $58,219,027 |
| Total Non Current Assets | $32,556,827 | $34,344,424 | $40,950,680 | $39,182,297 |
| Investmentin Financial Assets | $0 | $27,929 | - | - |
| Goodwill And Other Intangible Assets | $32,519,496 | $34,274,045 | $40,875,041 | $39,153,266 |
| Other Intangible Assets | $32,519,496 | $34,274,045 | $40,875,041 | $39,153,266 |
| Current Assets | $27,827,111 | $15,953,261 | $11,381,165 | $19,036,730 |
| Other Current Assets | $235,367 | $201,239 | $92,955 | $159,767 |
| Assets Held For Sale Current | $0 | $2,092,998 | - | - |
| Receivables | $7,261,597 | $689,438 | $3,119,612 | $39,437 |
| Other Receivables | $159,564 | $128,770 | $3,046,502 | - |
| Taxes Receivable | $7,102,033 | $560,668 | - | - |
| Cash Cash Equivalents And Short Term Investments | $20,330,146 | $12,969,585 | $8,168,598 | $18,837,526 |
| Cash And Cash Equivalents | $20,330,146 | $12,969,585 | $8,168,598 | $18,837,526 |
| Cash Financial | $20,330,146 | $12,969,585 | $8,168,598 | $18,837,526 |
| Other Non Current Assets | - | $27,929 | $27,929 | $27,929 |
| Accounts Receivable | - | $560,668 | $73,110 | $39,437 |
| Gross Accounts Receivable | - | $560,668 | $73,110 | $39,437 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,449,638 | $31,198,896 | $20,507,082 | $14,256,788 |
| Total Non Current Liabilities Net Minority Interest | $20,023,032 | $18,927,028 | $11,270,106 | $8,755,722 |
| Other Non Current Liabilities | $20,023,032 | $18,927,028 | $11,151,965 | $8,649,279 |
| Tradeand Other Payables Non Current | $0 | $0 | $118,141 | $106,443 |
| Non Current Deferred Liabilities | $0 | $0 | - | - |
| Current Liabilities | $10,426,606 | $12,271,868 | $9,236,976 | $5,501,066 |
| Other Current Liabilities | $2,388,868 | $2,767,285 | $5,460,621 | $3,932,529 |
| Current Deferred Liabilities | $1,201,334 | $1,644,941 | - | - |
| Payables And Accrued Expenses | $6,522,129 | $7,580,501 | $3,574,546 | $1,503,504 |
| Payables | $4,601,544 | $6,407,171 | $3,574,546 | $1,503,504 |
| Other Payable | $169,623 | $1,914,416 | $1,510,220 | $672,866 |
| Accounts Payable | $4,431,921 | $4,492,755 | $2,064,326 | $830,638 |
| Equity | ||||
| Common Stock Equity | $31,274,964 | $19,635,918 | $30,990,426 | $43,962,239 |
| Total Equity Gross Minority Interest | $29,934,299 | $19,098,789 | $31,824,762 | $43,962,239 |
| Stockholders Equity | $31,274,964 | $19,635,918 | $30,990,426 | $43,962,239 |
| Other Equity Interest | $593,174 | $593,174 | $1,498,789 | - |
| Gains Losses Not Affecting Retained Earnings | $9,158,580 | $26,483,781 | $7,234,644 | $4,907,209 |
| Other Equity Adjustments | $9,158,580 | $26,483,781 | $7,234,644 | $4,907,209 |
| Retained Earnings | $-101,754,609 | $-77,739,680 | $-45,631,800 | $-21,522,252 |
| Other | ||||
| Ordinary Shares Number | $1,651,270,413 | $321,440,475 | $250,848,547 | $195,342,511 |
| Share Issued | $1,651,270,413 | $321,440,475 | $250,848,547 | $195,342,511 |
| Tangible Book Value | $-1,244,531 | $-14,638,127 | $-9,884,615 | $4,808,973 |
| Invested Capital | $31,274,964 | $19,635,918 | $30,990,426 | $43,962,239 |
| Working Capital | $17,400,505 | $3,681,392 | $2,144,189 | $13,535,664 |
| Total Capitalization | $31,274,964 | $19,635,918 | $30,990,426 | $43,962,239 |
| Minority Interest | $-1,340,665 | $-537,129 | $834,337 | - |
| Capital Stock | $123,277,819 | $70,298,642 | $67,888,792 | $60,577,281 |
| Common Stock | $123,277,819 | $70,298,642 | $67,888,792 | $60,577,281 |
| Current Deferred Revenue | $1,201,334 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $314,275 | $279,143 | $201,808 | $65,034 |
| Current Accrued Expenses | $1,920,585 | $1,173,329 | - | - |
| Investments And Advances | $0 | $27,929 | - | - |
| Net PPE | $37,331 | $42,450 | $47,710 | $1,102 |
| Foreign Currency Translation Adjustments | - | $-380,071 | - | - |
| Available For Sale Securities | - | $27,929 | - | - |
| Gross PPE | - | $42,450 | $47,710 | $1,102 |
| Machinery Furniture Equipment | - | $42,450 | $47,710 | $1,102 |
Fetched: 2026-10-19
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,586,843 | $-16,042,407 | $-17,268,872 | $-26,710,169 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-25,586,843 | $-16,042,407 | $-16,200,110 | $-6,923,372 |
| Classesof Cash Receiptsfrom Operating Activities | $3,738,286 | $3,569,544 | $1,290,012 | $-6,923,372 |
| Other Cash Paymentsfrom Operating Activities | - | $3,387,683 | $1,085,879 | - |
| Other Cash Receiptsfrom Operating Activities | - | $3,387,683 | $1,085,879 | - |
| Investing Activities | ||||
| Investing Cash Flow | $1,236,278 | $-223,432 | $-1,068,762 | $-19,808,559 |
| Cash Flow From Continuing Investing Activities | $1,236,278 | $-223,432 | $-1,068,762 | $-19,808,559 |
| Net Other Investing Changes | $-856,720 | $-223,432 | - | $-27,929 |
| Capital Expenditure | - | - | $-1,068,762 | $-19,786,796 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $37,688,802 | $20,699,292 | $7,032,925 | $48,875,855 |
| Financing Cash Flow | $31,721,511 | $21,084,307 | $6,436,106 | $45,461,607 |
| Cash Flow From Continuing Financing Activities | $31,721,511 | $21,084,307 | $6,436,106 | $45,461,607 |
| Net Other Financing Charges | $-4,640,660 | $-1,152,612 | $-596,819 | $-3,373,053 |
| Net Common Stock Issuance | $37,688,802 | $20,699,292 | $7,032,925 | $48,875,855 |
| Common Stock Issuance | $37,688,802 | $20,699,292 | $7,032,925 | $48,875,855 |
| Repurchase Of Capital Stock | - | $-1,070,920 | $-596,819 | $-3,373,053 |
| Other | ||||
| Repayment Of Debt | $-1,326,630 | $-3,607,736 | $0 | $-48,178 |
| Issuance Of Debt | $0 | $5,145,364 | $0 | $6,982 |
| End Cash Position | $20,330,146 | $12,969,585 | $8,168,598 | $18,837,526 |
| Beginning Cash Position | $12,969,585 | $8,168,598 | $18,837,526 | $18,916 |
| Effect Of Exchange Rate Changes | $-10,385 | $-17,481 | $163,838 | $88,935 |
| Changes In Cash | $7,370,946 | $4,818,468 | $-10,832,766 | $18,729,675 |
| Net Issuance Payments Of Debt | $-1,326,630 | $1,537,627 | $0 | $-41,195 |
| Net Long Term Debt Issuance | $-1,326,630 | $1,537,627 | $0 | $-41,195 |
| Long Term Debt Payments | $-1,326,630 | $-3,607,736 | $0 | $-48,178 |
| Long Term Debt Issuance | $0 | $5,145,364 | $0 | $6,982 |
| Net Intangibles Purchase And Sale | $2,092,998 | $0 | $-1,037,128 | $-19,784,877 |
| Net PPE Purchase And Sale | $0 | $0 | $-31,634 | $-1,919 |
| Purchase Of PPE | $0 | $0 | $-31,634 | $-1,919 |
| Taxes Refund Paid Direct | $0 | $3,387,683 | $1,085,879 | - |
| Interest Received Direct | $558,797 | $35,249 | $101,267 | - |
| Classesof Cash Payments | $-29,883,926 | $-19,647,200 | $-17,591,389 | - |
| Paymentsto Suppliersfor Goodsand Services | $-29,883,926 | $-19,647,200 | $-17,591,389 | - |
| Receiptsfrom Customers | $3,738,286 | $181,861 | $204,133 | $-6,923,372 |
| Common Stock Payments | - | $-1,070,920 | $-596,819 | $-3,373,053 |
| Purchase Of Intangibles | - | - | $-1,037,128 | $-19,784,877 |
| Interest Received Cfi | - | - | - | $6,166 |
Fetched: 2026-10-19